In vivo analytical methods for polypeptide drugs

Abstract

Abstract: Polypeptide drugs provide a new field for new drug research, as well as one of the most active and rapid fields of new drug development. At present, how to determine the polypeptide drugs in the biological matrix is a difficulty in the world which faces to a lot of challenges.The widely used methods are ELISA and radiation isotope labeling. HPLC-MS /MS develops fast and will become the most important method for polypeptide drugs determination in vivo. This article will review the pros and cons, application status and development trend of several analytical method used in the world.

Key words: polypeptide drugs, bioassay, ELISA, stable isotope labeling, radiation isotope labeling, LCMS/MS

CLC Number:

R969

WANG Jing, GUAN Yong-biao. In vivo analytical methods for polypeptide drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(11): 1309-1314.

References

[1] Mire-Sluis AR.Progress in the use of biological assays during the development of biotechnology products[J]. Pharm Res, 2001, 18(9): 1239-1246.
[2] Thorpe R, Wadhwa M, Page C, et al. Bioassay s for the characterisation and control of therapeutic cytokines;Determination of potency[J]. Dev Biol Stand, 1999, 97: 61-71.
[3] Rose MP, Gaines Das RE, Balen AH.Definition and measurement of follicle stimulating hormone[J]. Endocr Rev, 2000, 21(1): 5-22.
[4] Piscitelli SC, ReissWG, Figg WD, et al. Pharmacokinetic studies with recombinant cytokines.Scientific issues and practical considerations[J]. Clin Pharmacokinet, 1997, 32(5): 368-381.
[5] Tanswell P, Modi N, Combs D, et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction[J]. Clin Pharmacokinet, 2002, 41(15): 1229-1245.
[6] Iacona I, Lazzarino M, Avanzini MA, et al. Rituximab (IDEC-C2B8): Validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study[J]. Ther Drug Monit, 2000, 22(3): 295-301.
[7] Cheung W, Minton N, Gunawardena K.Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly[J]. Eur J Clin Pharmacol, 2001, 57(5): 411-418.
[8] Alciato F, Sainaghi PP, Castello L, et al. Development and validation of an ELISA method for detection of growth arrest specific 6 (GAS6) protein in human plasma[J]. J Immunoassay Immunochem, 2008, 29(2): 167-180.
[9] Kobori H, Katsurada A, Miyata K, et al. Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA[J]. Am J Physiol Renal Physiol, 2008, 294(5): 1257-1263.
[10] McMartin C.Pharmacokinetics of peptides and proteins: Opportunities and challenges[J]. Adv Drug Res, 1992, 22:39-106.
[11] Toon S.The relevance of pharmacokinetics in the development of biotechnology products[J]. Eur J Drug Metab Pharmacokinet, 1996, 21(2): 93-103.
[12] WallisM, Gwilliam DJ, Wallis OC.Preparation and characterization of a recombinant DNA-derived ovine growth hormone variant internally labelled with sulphur-35[J]. J Mol Endocrinol, 1993, 11(3): 351-359.
[13] Wanying Q, Brodin T, Ceberg C, et al. Radio-iodinated and internally labelled (35S) IgM monoclonal antibodies in a syngenic rat model[J]. Acta Oncol, 1991, 30(3): 379-383.
[14] Nadeau RW, Satoh H, Scheide S, et al. A comparison of mass balance, pharmacokinetics and disposition of [¹⁴ C (U)] - and [¹²⁵ I] -recombinant human interleukin-2 in cynomolgus monkeys[J]. Drug Metab Dispos, 1995, 23(9): 904-909.
[15] Haskins NJ.The application of stable isotopes in biomedical research[J]. Biomed Mass Spectrom, 1982, 9(7): 267-277.
[16] Browne TR.Stable isotopes in clinical pharmacokinetic investigations[J]. Clin Pharmacokinet, 1990, 18(6): 423-433.
[17] Cossum PA, Dwyer KA, Roth M, et al. The disposition of a human relaxin (hRlx-2) inpregnant and nonpregnant rats[J]. Pharm Res, 1992, 9(3): 419-424.
[18] 戴舒佳, 廖智, 刘秀文, 等. 大鼠硬脊膜外和静脉注射[¹²⁵ I] 虎纹毒素-1后的药代动力学[J]. 中国药理学与毒理学杂志, 2004, 18(5): 344-351.
[19] 赵宁, 张英起, 王增禄, 等. 新型重组人肿瘤坏死因子在小鼠体内的药代动力学研究[J]. 第四军医大学学报, 2002, 23(12): 1065-1067.
[20] Garzone P, Colburn W, Mokotoff M, eds. Petides, peptoids, and proteins[M]. Cincinnati, OH:Harvey Whitney Books, 1991:73-79.
[21] Muller S, Hochhaus G.Metabolism of dynorphin A 1-13 in human blood and plasma[J]. Pharm Res, 1995, 12(8): 1165-1170.
[22] Muller S, Hutson A, Arya V, et al. Assessment of complex peptide degradation pathways via structured multicompartmental modeling approaches:the metabolism of dynorphin A1-13 and related fragments in human plasma[J]. J Pharm Sci, 1999, 88(9): 938-944.
[23] Yamaguchi K.Cold-spray ionization mass spectrometry: principle and applications[J]. JMass Spectrom, 2003, 38(5): 473-490.
[24] Yang JZ, Bastian KC, Moore RD, et al. Quantitative analysis of a model opioid peptide and its cyclic prodrugs in rat plasma using high-performance liquid chromatography with fluorescence and tandem mass spectrometric detection[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2002, 780(2): 269-281.
[25] Chang D, Kolis SJ, Linderholm KH, et al. Bioanalytical method development and validation for a large peptide HIV fusion inhibitor (Enfuvirtide, T-20) and its metabolite in human plasma using LC-MS /MS[J]. J Pharm Biomed Anal, 2005, 38(3): 487-496.
[26] Feng WY, Chan KK, Covey JM. Electrospray LC-MS MS quantitation, stability, and preliminary pharmacokinetics of bradykinin antagonist polypeptide B201 (NSC 710295) in the mouse[J]. J Pharm Biomed Anal, 2002, 28(3/4): 601-612.
[27] Zhang N, Fountain ST, Bi H, et al. Quantification and rapid metabolite identification in drug discovery using API time-of-flight LC /MS[J]. Anal Chem, 2002, 72(4): 800-805.